Skip to main content
ARS Home » Southeast Area » Athens, Georgia » U.S. National Poultry Research Center » Endemic Poultry Viral Diseases Research » Research » Publications at this Location » Publication #312601

Research Project: Intervention Strategies to Control and Prevent Enteric Viral Diseases of Poultry

Location: Endemic Poultry Viral Diseases Research

Title: Evaluation of bivalent Newcastle disease virus (NDV) vectored infectious laryngotracheitis vaccines in broiler chickens in the presence of NDV maternally derived antibody

Author
item Yu, Qingzhong
item Spatz, Stephen
item Zhang, Zhenyu - Northeast Agricultural University
item Yang, Jinlong - Chongqing Academy Of Animal Sciences
item Garcia, Maricarmen - University Of Georgia
item Zsak, Laszlo

Submitted to: American Association of Avian Pathologists
Publication Type: Abstract Only
Publication Acceptance Date: 1/2/2015
Publication Date: 7/11/2015
Citation: Yu, Q., Spatz, S.J., Zhang, Z., Yang, J., Garcia, M., Zsak, L. 2015. Evaluation of bivalent Newcastle disease virus (NDV) vectored infectious laryngotracheitis vaccines in broiler chickens in the presence of NDV maternally derived antibody [abstract]. In: Proceedings of the 2015 Annual Meeting of the American Association of Avian Pathologists, July 11-14, 2015, Boston, Massachusetts. p.21.

Interpretive Summary:

Technical Abstract: Previously we have demonstrated that Newcastle disease virus (NDV) recombinants expressing the infectious laryngotracheitis virus (ILTV) glycoproteins B (gB) or D (gD) protein conferred complete clinical protection against ILTV and NDV challenges in specific pathogen free (SPF) and 3 week old commercial boiler chickens. In the present study, we extended the evaluation of these vaccines in broiler chickens in the presence of maternally derived antibody (MDA) against NDV to assess the interference of MDA to these vaccines. The results showed that the NDV MDA moderately suppressed the immunoresponse to the NDV vector, however, the ILTV antigens expressed from the NDV vector were still sufficient to confer a significant protection against ILTV clinical disease.